ABSTRACT
Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.
ABSTRACT
La leucemia linfocítica crónica es el síndrome linfoproliferativo crónico más frecuente en nuestro país, existiendo una amplia heterogeneidad en su abordaje clínico. En la actualidad, en España no se dispone de guías de consenso nacionales similares a las publicadas en otros países para su diagnóstico, clasificación pronóstica y tratamiento. El presente trabajo revisa la evidencia científica actual y aborda cuestiones relacionadas con el diagnóstico, el estudio de extensión, la presencia de comorbilidades y la clasificación de escalas pronósticas, los esquemas de tratamiento habituales estratificados por grupos de riesgo, el tratamiento de las complicaciones asociadas tanto a la enfermedad como a los procedimientos, así como diferentes controversias que rodean a la enfermedad y su tratamiento. El documento, realizado con la colaboración de expertos nacionales, permite establecer unas recomendaciones de carácter práctico, con su correspondiente nivel de evidencia y grado de recomendación, que facilitarán el diagnóstico, tratamiento y seguimiento de los pacientes con leucemia linfocítica crónica (AU)
Chronic lymphocytic leukemia is the most common chronic lymphoproliferative disorder in Spain. The clinical management of this entity varies widely. Currently, in Spain, there are no national consensus guidelines, such as those published in other countries, to guide the diagnosis and treatment of this malignancy and the use of prognostic scores. This article reviews the current scientific literature and addresses issues on the diagnosis of chronic lymphocytic leukemia, the spread of the disease, the presence of comorbidities, the classification of prognostic scores, the common treatment regimens stratified by risk factors, and the management of complications associated with both the disease and its treatment, as well as the various controversies related to this entity. This document was drafted with the collaboration of national experts and aims to establish practical guidelines with their corresponding levels of evidence and grades of recommendation to guide the diagnosis, treatment and follow-up of patients with chronic lymphocytic leukemia (AU)
Subject(s)
Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/drug therapy , Chlorambucil/therapeutic use , Antibodies, Monoclonal/therapeutic useABSTRACT
Chronic lymphocytic leukemia is the most common chronic lymphoproliferative disorder in Spain. The clinical management of this entity varies widely. Currently, in Spain, there are no national consensus guidelines, such as those published in other countries, to guide the diagnosis and treatment of this malignancy and the use of prognostic scores. This article reviews the current scientific literature and addresses issues on the diagnosis of chronic lymphocytic leukemia, the spread of the disease, the presence of comorbidities, the classification of prognostic scores, the common treatment regimens stratified by risk factors, and the management of complications associated with both the disease and its treatment, as well as the various controversies related to this entity. This document was drafted with the collaboration of national experts and aims to establish practical guidelines with their corresponding levels of evidence and grades of recommendation to guide the diagnosis, treatment and follow-up of patients with chronic lymphocytic leukemia.
